key: cord-0885493-fv4e2u0f
authors: Jordan, Stanley C.; Shin, Bong-Ha; Gadsden, Terry-Ann M.; Chu, Maggie; Petrosyan, Anna; Vo, Ashley; Ammerman, Noriko; Sethi, Supreet; Najjar, Reiad; Huang, Ed; Peng, Alice; Toyoda, Mieko; Kumar, Sanjeev; Zhang, Ruan
title: Divergent Immune Responses to SARS-CoV-2 Vaccines in Immunocompromised Patients
date: 2021-09-20
journal: Transplantation
DOI: 10.1097/tp.0000000000003957
sha: 9f0b05a2e2500a0e6aba42f926ce1523d266c57d
doc_id: 885493
cord_uid: fv4e2u0f

Supplemental Digital Content is available in the text.

(Appendix 1, SDC, http://links.lww.com/TP/C290). Seven patients were identified from a cohort of 70 immunocompromised patients, with all demonstrating spikespecific IgG unresponsiveness 2-4 mo postvaccination. All had received treatment with B-cell modifying agents. We subsequently examined CD4 + /CD8 + T-cell-spike-specific immune responses in all patients and repeat examination after revaccination in 2 patients (see Appendix 1, SDC, http://links.lww.com/TP/C290, for Methods and Data). CD4 + /CD8 + T-cell responses are shown in Figure 1 and demonstrate robust CD4 + T-cell (0.94 ± 1.2%, Normal > 0.05%) and CD8 + T-cell (0.89 ± 1.2%, Normal > 0.05%) immune responses to spike peptides. Two patients receiving Johnson & Johnson booster vaccines demonstrated increased T-cell responses but remained spike IgG negative. This suggests that T-cell immune responses to SARS-CoV-2 vaccines are primal and retentive and that B-cell depletion before vaccine exposure prevents the cascade of progression of B-cell activation necessary for SARS-CoV-2 spike IgG production.

Absence of IgG responses to SARS-CoV-2 suggests patients be considered "unvaccinated." However, we show that patients treated with B-cell-modifying agents develop robust T-cell immune responses to SARS-CoV-2 without generating IgG responses. These observations should be considered in light of data presented by Peng et al showing robust CD4 + /CD8 + T-cell responses to SARS-CoV-2 after infection. A critical observation was the diversity of T-cell responses that likely extend beyond the persistence of spike antibody. IgG is necessary for sterilizing immunity and T-cells cannot prevent infection as antigen presentation is required, but T-cell immunity can be at the ready for viral elimination. This may provide an inside track for rapid deployment of SARS-CoV-2 immunity, and although not preventing infection, could alter the severity and duration of SARS-CoV-2 disease. 6 This is supported by data from Oberhardt et al 7 who recently showed that vaccine-induced CD8 + T cells were the main mediators of protection after vaccination since they emerged before detection of neutralizing antibody and expanded after booster vaccination. Thus, detection of T-cell immune responses in patients failing to generate spike-specific IgG may aid in a more comprehensive assessment of immunity to SARS-CoV-2, identifying patients who would no longer be considered "unvaccinated" based on negative spike-specific IgG. This likely has relevance to patients receiving B-cell directed therapies for autoimmune and hematologic diseases.

Innate and adaptive immune responses to SARS-CoV-2 in humans: relevance to acquired immunity and vaccine responses

A long-term perspective on immunity to COVID

T cells in COVID-19-united in diversity

Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients

Implications of defective immune responses in SARS-CoV-2 vaccinated organ transplant recipients

Oxford Immunology Network Covid-19 Response T cell Consortium; ISARIC4C Investigators. Broad and strong memory CD4 + and CD8 + T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19

Rapid and stable mobilization of CD8 + T cells by SARS-CoV-2 mRNA vaccine

Activated CD4 + T cells (IL-2 + TNFα + ) and CD8 + T cells (IFNγ + TNFα + ) are shown in the upper right-hand corner of each flow box. B, This figure shows immune responses to SARS-CoV-2 spike peptides in 2 patients who obtained external revaccination with the Johnson & Johnson vaccine

IL-2 + TNFα + ) and CD8 + T cells (IFNγ + TNFα + ) are shown in the upper right-hand corner of each flow box. IFNγ

IL, interleukin; P, patient; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2

The authors would like to express our gratitude to the members of the Transplant Immunotherapy Program and the Transplant Immunology Laboratory at Cedars-Sinai Medical Center for their dedication to improving patient outcomes and safety during the coronavirus disease 2019 pandemic. We would also like to thank the patients who participated in this study by donating their blood for analysis of SARS-CoV-2 reactive T-cells.